Heming Li | Molecular Biology | Research Excellence Award

Published on 28/11/2025 by Medical Lab Scientist

Dr. Heming Li | Molecular Biology | Research Excellence Award

Doctor | The first hospital of China Medical University | China

Dr. Heming Li is an oncology clinician-scientist whose research has generated 1,045 citations across 37 scientific documents with an h-index of 17, reflecting a sustained impact on translational cancer science. His work centers on liquid biopsy innovations, particularly circulating tumor cells (CTCs), tumor invasion and metastasis, and immunotherapy biomarkers in lung, gastric, and hepatobiliary cancers. Dr. Li is recognized for pioneering one of China’s earliest and most sensitive cell-surface vimentin (CSV)–based CTC detection platforms, integrating negative and positive enrichment to enhance diagnostic accuracy, reduce costs, and enable real-time monitoring of tumor evolution. His research spans EMT regulation, immune escape, metabolic reprogramming, and multi-omics characterization of metastatic pathways, leading to first-author and corresponding-author publications in high-impact journals such as The Lancet, Journal of Hematology & Oncology, Journal of Experimental & Clinical Cancer Research, Molecular Cancer, Cancer Letters, and Cell Death & Disease. He has elucidated mechanisms including IGF-IR signaling, KDM4A/STAT3-driven tumor progression, ICAM-1-mediated microenvironmental adaptation, and PD-L1 expression on CSV⁺ CTCs as a prognostic marker in gastric cancer. His recent studies have also advanced understanding of FGL1 as an immune checkpoint target and the biological significance of TROP2 in cancer therapeutics. As principal investigator, he has secured major national and provincial funding, including NSFC General and Young Programs, to study CTC-based biomarkers, immunotherapy prediction models, and metastasis-driving pathways. Through sustained contributions across liquid biopsy technology, molecular oncology, and clinically actionable biomarker development, Dr. Li has established a leading research profile shaping the future of precision cancer care.

Profile: Scopus

Featured Publications

1. Li, H., Yan, J., & Han, T. (2024). Combination strategies in advanced hepatocellular carcinoma: The CARES-310 trial. The Lancet, 404, 1403–1404.

2. Li, H., Zhu, Y., Xu, L., Han, T., Luan, J., Li, X., Liu, Y., Wang, Z., Liu, Q., Kong, X., Zou, C., Su, L., Hou, Y., Chen, X., Chen, L., Wang, R., Xu, Z., & Zhao, M. (2024). Cell surface vimentin as an emerging marker for CTCs and therapeutic target in advanced gastric cancer. Journal of Experimental & Clinical Cancer Research, 43, 129.

3. Qian, W., Zhao, M., Wang, R., & Li, H. (2021). Fibrinogen-like protein 1 (FGL1): The next immune checkpoint target. Journal of Hematology & Oncology, 14, 147.

4. Liu, M., Wang, R., Sun, X., Liu, Y., Wang, Z., Yan, J., Sun, M., & Li, H. (2020). PD-L1 expression on CSV⁺ CTCs predicts prognosis in gastric cancer. Molecular Oncology, 14, 865–881.

5. Li, H., Batth, I. S., Qu, X., Xu, L., Song, N., Wang, R., & Liu, Y. (2017). IGF-IR signaling in EMT and therapeutic targeting. Molecular Cancer, 16, 6.

Hamid Madanchi | Bioinformatics in Lab Medicine | Editorial Board Member

Published on 13/11/202513/11/2025 by Medical Lab Scientist

Mr. Hamid Madanchi | Bioinformatics in Lab Medicine | Editorial Board Member

Assistant Professor | Semnan University of Medical Sciences | Iran

Dr. Hamid Madanchi, Ph.D., is an Assistant Professor of Pharmaceutical Biotechnology at the Semnan University of Medical Sciences and an active researcher at the Pasteur Institute of Iran. His multidisciplinary research integrates pharmaceutical biotechnology, bioinformatics, immunoinformatics, and peptide-based drug design to develop novel therapeutics and vaccines. With extensive expertise in molecular cloning, protein engineering, computational biology, and antimicrobial peptide synthesis, Dr. Madanchi’s work focuses on the discovery and rational design of bioactive peptides with anticancer, antimicrobial, and antiviral properties. His recent investigations include the development of SARS-CoV-2 fusion inhibitors, multi-epitope vaccines against emerging pathogens, and nanobiocomposite scaffolds for biomedical applications. Dr. Madanchi has authored and co-authored numerous peer-reviewed articles in high-impact journals such as Journal of Biomolecular Structure and Dynamics, Scientific Reports, Probiotics and Antimicrobial Proteins, and BMC Bioinformatics. His scientific contributions also include studies on peptide-based drug delivery systems, targeted cancer therapies, and computational vaccine design. As principal investigator on multiple national research projects, he has led efforts in epitope-based vaccine construction, antiviral peptide discovery, and bioinformatics-driven drug repurposing. Beyond research, Dr. Madanchi has played an important role in mentoring graduate students and advancing pharmaceutical biotechnology education in Iran. His ongoing work continues to bridge experimental and computational methods for the discovery of next-generation therapeutic biomolecules addressing global health challenges.

Profile: ORCID

Featured Publications

1. Yamchi, A., Madanchi, H., Khazaei, V., Behrouzikhah, M., Abbasi, H., Salehi, M., Moradi, N., & Sanami, S. (2024). Designing a multi-epitope vaccine against the SARS-CoV-2 variant based on an immunoinformatics approach. Current Computer-Aided Drug Design, 20(3), 274–290.

2. Lahimchi, M. R., Madanchi, H., Ahmadi, K., Shahbazi, B., & Yousefi, B. (2024). In silico designing a novel TLR4-mediating multiepitope vaccine against monkeypox via advanced immunoinformatics and bioinformatics approaches. Journal of Biomolecular Structure and Dynamics, 42(4), 2094–2110.

3. Khadijeh, A., Farasat, A., Rostamian, M., Johari, B., & Madanchi, H. (2021). Enfuvirtide, an HIV-1 fusion inhibitor peptide, can act as a potent SARS-CoV-2 fusion inhibitor: An in silico drug repurposing study. Journal of Biomolecular Structure and Dynamics.

4. Eivazzadeh-Keihan, R., Radinekiyan, F., Aliabadi, H. A. M., & Madanchi, H. (2021). Chitosan hydrogel/silk fibroin/Mg(OH)₂ nanobiocomposite as a novel scaffold with antimicrobial activity and improved mechanical properties. Scientific Reports, 11, 650.

5. Madanchi, H., Kiasari, R. E., Mousavi, S. J., Johari, B., Shabani, A. A., & Sardari, S. (2020). Design and synthesis of lipopolysaccharide-binding antimicrobial peptides based on truncated rabbit and human CAP18 peptides and evaluation of their action mechanism. Probiotics and Antimicrobial Proteins, 12(3), 853–864.

John Lin | Research Methods in Medical Lab Science | Best Researcher Award

Published on 22/10/202522/10/2025 by Medical Lab Scientist

Dr. John Lin | Research Methods in Medical Lab Science | Best Researcher Award

Co-CEO | Frontage Laboratories, Inc | United States

Dr. John Lin is a distinguished research scientist affiliated with Frontage Laboratories in Exton, United States. His scientific contributions span analytical chemistry, bioanalysis, and neurodegenerative disease biomarker development. With a total of 30 publications, Dr. Lin’s research has garnered 568 citations, reflecting his consistent impact in the analytical sciences. His h-index of 13 demonstrates both productivity and citation influence across multiple studies. Notably, his recent work, “Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform” (Journal of Prevention of Alzheimer’s Disease,), highlights his contribution to Alzheimer’s disease diagnostics. His earlier research includes the development and validation of LC-MS/MS and LC-HRMS methods for protein and antibody–drug conjugate quantification, published in Bioanalysis and Analytical and Bioanalytical Chemistry, respectively. Over his career, Dr. Lin has collaborated with over 230 co-authors, indicating his strong engagement in interdisciplinary research networks. His pioneering work supports precision measurement in clinical and pharmaceutical sciences, particularly enhancing biomarker quantitation technologies. Dr. Lin’s research excellence continues to influence bioanalytical method development and translational applications in clinical laboratory sciences, solidifying his reputation as a leading figure in analytical biochemistry and assay validation research

Profile: Scopus

Featured Publications

1. Lin, Z. (2024). Validation of an ultra-sensitive method for quantitation of phospho-tau 217 (pTau217) in human plasma, serum, and CSF using the ALZpath pTau217 assay on the Quanterix HD-X platform. Journal of Prevention of Alzheimer’s Disease.

2. Lin, Z. (2022). Development and validation of an LC-MS/MS method for the quantification of fascin proteins in human serum. Bioanalysis.

3. Lin, Z. (2020). Accurate determination of drug-to-antibody ratio of interchain cysteine-linked antibody–drug conjugates by LC-HRMS. Analytical and Bioanalytical Chemistry.

4. Lin, Z. (2019). Quantitative bioanalytical method development for biotherapeutics. Journal of Chromatography B.

5. Lin, Z. (2018). Optimization of analytical workflows for protein quantitation in biological matrices. Journal of Pharmaceutical and Biomedical Analysis.

Heming Li | Molecular Biology | Research Excellence Award

Dr. Heming Li | Molecular Biology | Research Excellence Award

Featured Publications

Hamid Madanchi | Bioinformatics in Lab Medicine | Editorial Board Member

Mr. Hamid Madanchi | Bioinformatics in Lab Medicine | Editorial Board Member

Featured Publications

John Lin | Research Methods in Medical Lab Science | Best Researcher Award

Dr. John Lin | Research Methods in Medical Lab Science | Best Researcher Award

Featured Publications

RECOMMENDED

Mail us